CYC.AX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 08:10):
Our systems believe the stock currently is undervalued by 0.96% compare to its pairs and should correct upwards.

Stats
Dagens volum	42 669
Gjennomsnittsvolum	62 805
Markedsverdi	175.60M
EPS	$-0.0192 ( Q4 \| 2023-12-31 )
Neste inntjeningsdato	( $0 ) 2024-08-19
Last Dividend	$0.00500 ( 2023-09-01 )
Next Dividend	$0 ( N/A )
P/E	-31.60 (Sector) 0 (Industry) 0
ATR14	$0.0230 (1.44%)

AHX.AX -2.90%

ALC.AX 6.25%

ANN.AX -2.41%

AT1.AX 0.00%

AVR.AX 0.00%

CAJ.AX -4.76%

CAU.AX 0.00%

CDX.AX -7.14%

CGS.AX -0.89%

COH.AX -2.89%

CYC.AX -6.51%

EBO.AX -1.81%

EHE.AX 0.33%

EMD.AX 12.20%

EMV.AX -11.11%

FPH.AX -1.26%

HLA.AX 0.17%

HLS.AX -4.33%

HMD.AX 13.04%

IBX.AX -1.18%

IDX.AX -3.00%

IHL.AX -10.87%

IMR.AX -0.94%

IPD.AX -1.39%

M7T.AX -0.78%

MDR.AX -5.00%

MVF.AX -3.11%

MX1.AX -3.61%

NAN.AX -4.01%

NTI.AX 1.43%

NXS.AX -6.38%

ONE.AX -3.75%

PCK.AX 3.70%

PME.AX -5.31%

PNV.AX -4.90%

PSQ.AX -0.79%

REG.AX -3.21%

RHC.AX -1.60%

RHY.AX -3.23%

RSH.AX 13.04%

SHL.AX -2.43%

SIG.AX -2.35%

SNZ.AX 0.81%

TTB.AX 0.00%

UBI.AX 0.00%

VHT.AX 0.44%

VTI.AX 0.00%

Korrelasjon (AI algo v.1.1b): Undervalued: 0.96% $1.610 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Cyclopharm Ltd Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cyclopharm Ltd Økonomi

Annual	2023
Omsetning:	$27.14M
Bruttogevinst:	$4.50M (16.57 %)
EPS:	$-0.0507

FY	2023
Omsetning:	$27.14M
Bruttogevinst:	$4.50M (16.57 %)
EPS:	$-0.0507

FY	2022
Omsetning:	$23.22M
Bruttogevinst:	$5.94M (25.58 %)
EPS:	$-0.0717

FY	2021
Omsetning:	$17.70M
Bruttogevinst:	$12.66M (71.52 %)
EPS:	$-0.0658

Financial Reports:

No articles found.

Cyclopharm Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.00500 (N/A)	$0 (N/A)	$0.00500 (N/A)	$0 (N/A)	$0.00500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Cyclopharm Ltd Dividend Information - Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00496	2015-10-02
Last Dividend	$0.00500	2023-09-01
Next Dividend	$0	N/A
Payout Date	2023-09-11
Next Payout Date	N/A
# dividends	17	--
Total Paid Out	$0.0848	--
Avg. Dividend % Per Year	0.45%	--
Score	1.35	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-12-13)

$0.00509 Estimate 7.35 %

Dividend Stability

0.29 Very Poor

Dividend Score

1.35

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2015	$0.00496	1.79%
2016	$0.00992	1.92%
2017	$0.00996	1.10%
2018	$0.0100	1.00%
2019	$0.0100	0.93%
2020	$0.0100	0.82%
2021	$0.0100	0.39%
2022	$0.0100	0.61%
2023	$0.0100	0.85%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
01 Sep 2023	$0.00500	30 Nov -0001	04 Sep 2023	11 Sep 2023
27 Mar 2023	$0.00500	30 Nov -0001	28 Mar 2023	04 Apr 2023
02 Sep 2022	$0.00500	30 Nov -0001	05 Sep 2022	12 Sep 2022
04 Apr 2022	$0.00500	30 Nov -0001	05 Apr 2022	12 Apr 2022
03 Sep 2021	$0.00500	30 Nov -0001	06 Sep 2021	13 Sep 2021
01 Apr 2021	$0.00500	30 Nov -0001	06 Apr 2021	13 Apr 2021
04 Sep 2020	$0.00500	25 Aug 2020	07 Sep 2020	14 Sep 2020
30 Mar 2020	$0.00500	26 Feb 2020	31 Mar 2020	07 Apr 2020
06 Sep 2019	$0.00500	22 Aug 2019	09 Sep 2019	16 Sep 2019
05 Apr 2019	$0.00500	27 Feb 2019	08 Apr 2019	15 Apr 2019
07 Sep 2018	$0.00500	23 Aug 2018	10 Sep 2018	17 Sep 2018
06 Apr 2018	$0.00500	26 Feb 2018	09 Apr 2018	16 Apr 2018
01 Sep 2017	$0.00500	28 Aug 2017	04 Sep 2017	11 Sep 2017
31 Mar 2017	$0.00496	22 Feb 2017	03 Apr 2017	10 Apr 2017
02 Sep 2016	$0.00496	19 Aug 2016	05 Sep 2016	12 Sep 2016
11 Apr 2016	$0.00496	24 Feb 2016	12 Apr 2016	19 Apr 2016
02 Oct 2015	$0.00496	26 Aug 2015	07 Oct 2015	14 Oct 2015

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
EZL.AX	Dividend Royal	2024-02-02	Semi-Annually	24	11.64%	8.24
GRR.AX	Dividend Royal	2024-03-12	Semi-Annually	14	11.88%	7.99
RKN.AX	Dividend Royal	2023-08-31	Annually	22	15.73%	7.24
TWR.AX	Dividend King	2024-06-12	Annually	25	5.98%	7.21
YAL.AX	Dividend Royal	2024-03-12	Annually	7	12.76%	7.18
SHM.AX	Dividend Royal	2024-03-14	Semi-Annually	9	14.97%	7.14
HZN.AX	Dividend Royal	2024-04-18	Semi-Annually	4	18.99%	7.06
BHP.AX	Dividend Royal	2024-03-07	Semi-Annually	37	6.46%	6.97
CDD.AX	Ex Dividend King	2024-05-24	Annually	21	91.43%	6.79
KSL.AX	Dividend Royal	2024-03-05	Semi-Annually	9	9.58%	6.77

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.178	1.500	-3.57	-5.35	[0 - 0.5]
returnOnAssetsTTM	-0.102	1.200	-3.41	-4.10	[0 - 0.3]
returnOnEquityTTM	-0.140	1.500	-2.67	-4.00	[0.1 - 1]
payoutRatioTTM	-0.188	-1.000	-1.882	1.882	[0 - 1]
currentRatioTTM	3.48	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.26	0.800	1.391	1.113	[0.8 - 2.5]
cashRatioTTM	1.353	1.500	3.60	5.39	[0.2 - 2]
debtRatioTTM	0.0921	-1.500	8.47	-10.00	[0 - 0.6]
interestCoverageTTM	-44.83	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.0765	2.00	-0.0255	-0.0510	[0 - 30]
freeCashFlowPerShareTTM	-0.0822	2.00	-0.0411	-0.0822	[0 - 20]
debtEquityRatioTTM	0.131	-1.500	9.48	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.131	1.000	-1.147	-1.147	[0.2 - 0.8]
operatingProfitMarginTTM	-0.368	1.000	-9.35	-9.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.703	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.574	0.800	9.51	7.61	[0.5 - 2]
Total Score				-0.485

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-31.83	1.000	-3.32	0	[1 - 100]
returnOnEquityTTM	-0.140	2.50	-1.714	-4.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0822	2.00	-0.0274	-0.0822	[0 - 30]
dividendYielPercentageTTM	0.314	1.500	2.14	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0765	2.00	-0.0255	-0.0510	[0 - 30]
payoutRatioTTM	-0.188	1.500	-1.882	1.882	[0 - 1]
pegRatioTTM	-1.746	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.273	1.000	-9.33	0	[0.1 - 0.5]
Total Score				-2.67

Cyclopharm Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cyclopharm Ltd

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.